CytoSorbents Appoints Peter J. Mariani Chief Financial Officer CytoSorbents CFO Kathleen P. Bloch Retires PRINCETON, N.J.

CytoSorbents Appoints

Peter J. Mariani Chief Financial Officer

CytoSorbents CFO Kathleen P. Bloch Retires

PRINCETON, N.J., August 13, 2024 -- CytoSorbents

Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using

blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial

Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently,

Kathleen P. Bloch, CytoSorbents' current CFO, announced her retirement from the Company effective as of the close of business today,

and will continue to serve in an advisory role as a consultant to enable an effective transition.

Mr. Mariani brings over 25 years of experience

as a valued partner and strategic financial leader across several high growth medical device companies. Prior to joining CytoSorbents,

Mr. Mariani served as CFO of Axogen, Inc (NASDAQ: AXGN), a medical technology company focused on peripheral nerve repair, from March 2016

to December 2023, most recently as its Executive Vice President & CFO from March 2021 to December 2023. At Axogen, Mr. Mariani was

responsible for all finance and accounting functions, investor relations, information technology and security, and Global Quality. During

his tenure, Axogen grew annual revenue from $27 million to nearly $160 million, expanded from one to four nerve repair clinical applications,

raised approximately $250 million of capital, executed a comprehensive clinical evidence development and publication strategy, and completed

a long-term facility build-out.

Dr. Chan stated, "Pete is a seasoned and

accomplished medical device CFO whose many successes at high growth publicly-traded companies such as Axogen, Hansen Medical, and Guidant

Corporation, speak for themselves. He has consistently demonstrated a disciplined and rigorous approach to financial management, operational

excellence, and strategic development both domestically and internationally that aligns perfectly with our next phase of expected rapid

growth. Importantly, CytoSorbents today shares many similarities to Axogen when Pete joined as CFO in 2016, including with respect to

its size, revenue base, U.S. market opportunity, and high margin business model. He has proven his ability to fund, scale, and manage

impressive growth. As we pursue U.S. and Canadian marketing approval for DrugSorb-ATR and drive our OUS business with CytoSorb, we believe

Pete will be an outstanding fit where his deep global experience and insight is expected to be vital to our success. We are thrilled to

have Pete join CytoSorbents and be a key member of the management team."

Prior to Axogen, Mr. Mariani was the Chief Financial

Officer of Lensar, Inc., (NASDAQ: LNSR) which at the time was privately-held and a global leader in next generation femtosecond laser

technology for refractive cataract surgery. Prior to Lensar, he served as Chief Financial Officer at Hansen Medical, Inc., a publicly

traded company that designed and manufactured medical robotics for positioning and control of catheter-based technologies. Mr. Mariani's

career also includes 12 years with Guidant Corporation, a global leader in the development and sale of medical devices for the treatment

of cardiovascular disease. During his tenure at Guidant, he held senior financial positions of increasing importance, including Vice President

of Finance and Administration, Guidant Japan, and Corporate Vice President, Controller and Chief Accounting Officer. He started his career

at Ernst and Young, LLP, where he served a diverse client base as a Certified Public Accountant. Mr. Mariani earned a Bachelor of Science

in accounting from Indiana University.

"I am excited to join CytoSorbents during

this pivotal time in the Company's history." stated Mr. Mariani. "The potential future marketing approval of DrugSorb-ATR

by the U.S. Food and Drug Administration (FDA) and Health Canada would provide an exciting U.S. and Canadian entry point for the Company's

technology in the large and important cardiac surgery market. The anticipated win-win-win value proposition for patients, surgeons, and

hospitals, if approved, appears extremely compelling. Meanwhile the opportunity for CytoSorb in critical care and cardiac surgery

worldwide is massive with the anticipated prospects of stronger and sustained growth ahead. I look forward to partnering with this talented

and dedicated team to further develop and execute our long-term growth strategy and bring improved outcomes to as many patients as possible

with CytoSorbents' life-saving blood purification therapies."

Dr. Chan concluded, "As we welcome

Pete to CytoSorbents, we remain indebted to Kathy Bloch for her more than 11 years of dedication and leadership at the Company

as a trusted colleague and friend, and for all of her contributions that have helped us achieve the success we have today. In particular,

after her retirement as our CFO in March 2023, and interim CFO consultancy, Kathy selflessly came back in August 2023 to reprise her role

as full-time CFO, and in the intervening 12 months, helped to secure the future of the Company with two key financings and orchestrating

our cash conservation strategy. We are glad she will continue as a consultant to help manage a smooth CFO transition. On behalf of the

CytoSorbents Board of Directors, its management team, and employees, we wish Kathy an enjoyable, relaxing, and well-deserved retirement."

About CytoSorbents Corporation

Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery

through blood purification. Its lead product, CytoSorb , is approved in the European

Union and distributed in 76 countries worldwide. It is an extracorporeal cytokine adsorber that reduces "cytokine storm"

or "cytokine release syndrome" in common critical illnesses that can lead to massive inflammation, organ failure and patient

death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also

used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative

complications, including severe bleeding and multiple organ failure. As of June 30, 2024, more than 248,000 CytoSorb devices have

been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber.

Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma,

respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also

received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with

impending or confirmed respiratory failure. CytoSorb is not yet approved in the United States.

antithrombotic removal system, an investigational device based on the same polymer technology as CytoSorb, has received two FDA

Breakthrough Device Designations, one for the removal of ticagrelor and

another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in

a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The Company has completed the FDA-approved, randomized, controlled

STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 140 patients at approximately 30 centers in U.S. and Canada to

evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and

undergoing cardiothoracic surgery. This pivotal study is intended to support U.S. FDA and Health Canada marketing

approval for DrugSorb-ATR in this application.

purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood

and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other

funding of approximately $50 million from DARPA, the U.S. Department of Health and Human Services (HHS),

the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S.

Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous

marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and

international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY , CytoSorb-XL ,

HemoDefend-RBC , HemoDefend-BGA , VetResQ , K+ontrol , DrugSorb , ContrastSorb, and

others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or

Forward-Looking Statements

release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities

Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives,

future targets and outlooks for our business, representations and contentions, the timing of our expected regulatory submissions and our

expectations with respect to the accretive value that Mr. Mariani will bring to the Company, and are not historical facts and typically

are identified by use of terms such as "may," "should," "could," "expect," "plan,"

"anticipate," "believe," "estimate," "predict," "potential," "continue"

and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements

in this press release represent management's current judgment and expectations, but our actual results, events and performance could

differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but

are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated

by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued

by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution

you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any

forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal

U.S. Company Contact:

305 College Road East

Investor Relations Contact:

LifeSci Advisors, LLC